allogeneic CAR T-cell therapy (UPMC/Avalon/University of Pittsburgh)

N/A

Report date: 2025/03/14 16:20:46

Base Information

Drug Nameallogeneic CAR T-cell therapy (UPMC/Avalon/University of Pittsburgh)

Drug Alias Nameoff-the-shelf CAR-based cancer immunotherapy (UPMC/Avalon/University of Pittsburgh)CAR T-cell therapy (UPMC/Avalon/University of Pittsburgh)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionT lymphocytes stimulantsImmunostimulants

TargetsUpdating

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAvalon Globocare Corp

China Registration ClassN/A

Develop Information

Active CompaniesAvalon Globocare Corp UPMC Hillman Cancer Center University Of Pittsburgh

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A